Mycozyl HC
RxNorm 2671298· TOLNAFTATE, HYDROCORTISONE· TOPICAL
Corticosteroid [EPC] · PURETEK CORPORATION
Indications and usage
INDICATIONS AND USAGE: Mycozyl HC ™ is indicated for treatment of fungal infection of the skin, skin around the nail, and for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and administration
DOSAGE AND ADMINISTRATION: Clean the affected area and dry thoroughly. Apply a thin layer of the product over affected area twice daily (morning and night) paying special attention to the edges of the nail, cuticles, and skin around the nails or as directed by a doctor.
Warnings
WARNINGS: For External Use Only. Not For Ophthalmic Use
Contraindications
CONTRAINDICATIONS: This product is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Pregnancy
Pregnancy: Teratogenic effects - Pregnancy Category C . Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well -controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
Nursing mothers
Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.
Adverse reactions (label)
ADVERSE REACTIONS: The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
KR · 한국Products in Korea (10)
- 엠엘이톨나프테이트크림(수출용)(주)네오팜
- 엠엘이톨나프테이트크림(수출용)(주)네오팜
- 엠엘이톨나프테이트크림(수출용)(주)네오팜
- 티나덤액(톨나프테이트액)동광제약(주)
- 세로판액(톨나프테이트)삼성제약(주)
- 톨라프크림(톨나프테이트)(수출용)태극제약(주)
- 톨라프크림(톨나프테이트)(수출용)태극제약(주)
- 톨라프크림(톨나프테이트)(수출용)태극제약(주)
- 톨라프크림(톨나프테이트)(수출용)태극제약(주)
- 톨라프크림(톨나프테이트)(수출용)태극제약(주)
View more: Full FDA label on DailyMed →Label effective 20231211